Limited Efficacy of Meningococcal B Vaccine

Two doses of 4CMenB vaccine protected only 66% of vaccinees against a serogroup B meningococcal outbreak strain.

A quadrivalent meningococcal vaccine against serogroups A, C, Y and W-135 is now being given to U.S. adolescents. However, concerns have remained regarding disease due to serogroup B meningococcal strains, for which vaccine development has been difficult. In 2015, two vaccines targeting serogroup B strains were approved by the FDA. Researchers now report the results of a prelicensure trial of one of these, the 4CMenB vaccine, to protect students at a university experiencing an outbreak of a serogroup B meningococcal disease.

Researchers enrolled 607 students, of whom 499 received two doses of the 4CMenB vaccine 10 weeks apart in accordance with the recommended schedule. Eight weeks after the second immunization, only 66.1% of the vaccine rec…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Limited Efficacy of Meningococcal B Vaccine

Topics

Reviewing Author